Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy

Fabio A. Iannotti, Ester Pagano, Ombretta Guardiola, Simone Adinolfi, Valentina Saccone, Silvia Consalvi, Fabiana Piscitelli, Elisabetta Gazzerro, Giuseppe Busetto, Diego Carrella, Raffaele Capasso, Pier Lorenzo Puri, Gabriella Minchiotti, Vincenzo Di Marzo

Research output: Contribution to journalArticlepeer-review

Abstract

The endocannabinoid system refers to a widespread signaling system and its alteration is implicated in a growing number of human diseases. However, the potential role of endocannabinoids in skeletal muscle disorders remains unknown. Here we report the role of the endocannabinoid CB1 receptors in Duchenne’s muscular dystrophy. In murine and human models, CB1 transcripts show the highest degree of expression at disease onset, and then decline overtime. Similar changes are observed for PAX7, a key regulator of muscle stem cells. Bioinformatics and biochemical analysis reveal that PAX7 binds and upregulates the CB1 gene in dystrophic more than in healthy muscles. Rimonabant, an antagonist of CB1, promotes human satellite cell differentiation in vitro, increases the number of regenerated myofibers, and prevents locomotor impairment in dystrophic mice. In conclusion, our study uncovers a PAX7–CB1 cross talk potentially exacerbating DMD and highlights the role of CB1 receptors as target for potential therapies.

Original languageEnglish
Article number3950
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Fingerprint Dive into the research topics of 'Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this